Summary

The peptide therapeutics market is expected to grow at a strong CAGR of around 9% during the forecast period owing to the surge in the incidence of cancer, rising research and development activities for the development of novel peptide therapeutics, and the development of a novel pipeline of drugs. Moreover, chronic diseases like diabetes and cardiovascular diseases are the foremost causes of morbidity and mortality worldwide, as per the World Health Organization (WHO). Chronic disease rates have skyrocketed globally, advancing across all regions and affecting all socioeconomic classes. Chronic diseases were estimated to cause 73 percent of all deaths and 60 percent of the global disease burden in 2020. As a result, the rising prevalence of chronic diseases increases the demand for effective therapeutics, which is anticipated to drive the market. Furthermore, the technological development and introduction of new peptide therapeutics for treating chronic diseases like cancer are also fueling the growth of the studied market. For instance, in May 2021, ISSAR Pharmaceuticals decided to license its peptide-based new NCEs with pre-IND filing. Thus, the above-mentioned factors are driving the growth of the market in the coming years.

Some of the major players operating in the market include AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Lilly; Sanofi; GSK plc; Novartis AG; and Takeda Pharmaceutical Company Limited. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report
“Amongst application, the metabolic segment held a significant share of the market in 2021”
Based on application, the market is segmented into cancer, metabolic, cardiovascular disorders, respiratory, hematological disorders, anti-infection, dermatology, CNS, and others. The metabolic segment held a significant share of the market in 2021. The rising geriatric population and associated surge in the prevalence of metabolic disorders are major factors contributing to segment growth. Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by progressive glucocerebroside storage in macrophages, predominantly in bone, bone marrow, liver, and spleen. In July 2022, an article published in the journal JPHO asserted that the prevalence of GD in global birth was 1.5 cases per 100,000 live births. The overall global prevalence of GD was 0.9 cases per 100,000 inhabitants. The high prevalence of such metabolic disorders is fueling the demand for peptide therapeutics for treating metabolic disorders, thereby driving the growth of the studied market.

“Amongst drug type, the generic category to grow with high CAGR during the forecast period”
By drug type, the market is bifurcated into branded and generic drugs. The generic category is anticipated to grow with a significant CAGR during the forecast period. Generic drugs are generally priced 50%-65% lower than branded drugs, thus increasing their adoption among individuals. Moreover, the loss of patents for novel biologic drugs and increasing investments in the development of generic drugs by pharmaceutical giants is propelling the growth of the segment.
“Amongst distribution channel, the hospital pharmacies segment held a dominant share of the market in 2021”
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies held a dominant share of the market in 2021. Several factors such as an increase in the number of hospitalization due to various acute and chronic diseases, and increasing prescriptions are driving the demand for peptide therapeutics.

“APAC to grow with high CAGR during the forecast period”
APAC is expected to grow with significant CAGR during the forecast period due to untapped opportunities, low cost for raw materials, a large number of companies offering outsourcing services, a thriving biotech industry, and rising research and development activities. For instance, in December 2022, PeptiDream announced a collaboration with Eli Lilly for the discovery of novel peptide drug conjugates. Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (PDPS) technology for use as PDCs against targets of interest to Merck.

Peptide Therapeutics Market Report Coverage
Base year
・2021
Forecast period
・2022-2030
Growth momentum
・Accelerate at a CAGR of 9%
Market size 2021
・USD 25 billion
Regional analysis
・North America, Europe, APAC, Rest of the World
Major contributing region
・Asia-Pacific is expected to grow at the highest CAGR during the forecasted period
Key countries covered
・U.S., Canada, Germany, United Kingdom, Spain, Italy, France, China, Japan, and India
Companies profiled AbbVie Inc.; F. Hoffmann-La Roche Ltd; Amgen Inc.; Pfizer Inc.; Bristol-Myers Squibb Company; Lilly; Sanofi; GSK plc; Novartis AG; and Takeda Pharmaceutical Company Limited
Report Scope
・Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Demand and Supply Side Analysis; Competitive Landscape; Company Profiling
Segments Covered
・By Drug Type; By Route of Administration; By Application; By Distribution Channel; By Region/Country

Reasons to buy this report:
• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.
• The report presents a quick review of overall industry performance at one glance.
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolios, expansion strategies, and recent developments.
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.
• The study comprehensively covers the market across different segments.
• Deep dive regional level analysis of the industry.

Customization Options:
The global peptide therapeutics market can further be customized as per the requirement or any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

ページTOPに戻る

Table of Contents